| Date Filed | Type | Description |
| 08/17/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/17/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/10/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 8.2% stake in Forte Biosciences, Inc. |
| 07/06/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 10% stake in Unicycive Therapeutics, Inc. |
| 06/30/2023 |
SC 13D/A
| BIOTECHNOLOGY VALUE FUND L P reports a 35.8% stake in MoonLake Immunotherapeutics |
| 06/30/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 7.1% stake in Revolution Medicines, Inc. |
| 05/30/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 9.8% stake in Janux Therapeutics, Inc. |
| 03/24/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 5.1% stake in IDEAYA Biosciences, Inc. |
| 03/20/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/16/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 5% stake in Aclaris Therapeutics, Inc. |
| 03/06/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P has filed a Schedule 13D for ASLAN Pharmaceuticals Limited |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 12.6% stake in Molecular Partners AG |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 4.6% stake in IDEAYA Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 6.9% stake in Galmed Pharmaceuticals Ltd. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 6.4% stake in Merus N.V. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 6.5% stake in 89bio, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 8.7% stake in POINT Biopharma Global Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 5.1% stake in Crinetics Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 3.2% stake in Arcus Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 0% stake in Relmada Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 1.4% stake in Cogent Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 16.4% stake in Cullinan Oncology, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 2.1% stake in Syndax Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 10.5% stake in Calliditas Therapeutics AB |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 10% stake in Calithera Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 0% stake in Spero Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 8.1% stake in AN2 Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 5.8% stake in Sutro Biopharma, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 5.6% stake in Viridian Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 5.2% stake in Aileron Therapeutics Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 4.9% stake in Aclaris Therapeutics, Inc. |
| 02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/06/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/03/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 9.3% stake in Zymeworks Inc. |
|